CHUM installs CyberKnife system for effective cancer treatment in Canada

NewsGuard 100/100 Score

Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery today announced that Centre Hospitalier de l'Universite de Montreal (CHUM) has installed a CyberKnife(R) Robotic Radiosurgery System at Hopital Notre-Dame du CHUM, in Montreal, Canada.

''The addition of the CyberKnife to the CHUM's Radio-oncology Department is a definite asset for our treatment program, offering another alternative to our patients and consolidating even further the CHUM's role as a Canadian leader in the field of oncology," said Jean-Paul Bahary, M.D., F.R.C.P. (C), Head, Radio-oncology Department, Centre hospitalier de l'Universite de Montreal.

CHUM, one of the largest radiation oncology centers in Canada, will utilize the CyberKnife System to treat both intracranial and extracranial applications including those in the lung, spine and prostate.

"Since announcing CHUM's purchase of a CyberKnife System, doctors and patients have been eager to see world class radiosurgery come to Canada," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "We are very excited to announce that the System has been installed and has begun treating patients."

Source: http://www.accuray.com

Comments

  1. Sioi Solomon Sioi Solomon   says:

    My Dad has a brain tumour, please advise how can we access this treatment. I can send you the current MRI reports for you to ascertain gravity of the quandry. We are based in Tanzania ( East Africa) please help asap - Thanks

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New blood test shows promise in early detection of ovarian cancer